valproic acid has been researched along with Cancer of Prostate in 46 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid is a well-known antiepileptic drug that was recently discovered to have a wide-spectrum antitumoral action in several tumors." | 5.33 | Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. ( Angelucci, A; Bernardini, S; Bologna, M; Dolo, V; Federici, G; Gravina, GL; Miano, R; Millimaggi, D; Valentini, A; Vicentini, C, 2006) |
| "Only a minority of men succumb to prostate cancer (PCa)." | 1.43 | Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models. ( Bratslavsky, G; Byler, T; Caza, T; Chelluri, R; Reeder, JE; Woodford, MR, 2016) |
| "Valproic acid could suppress invasiveness of prostate cancer cell lines PC3 and Du145, possibly through multiple pathways other than the SAMD4 pathway." | 1.40 | Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness. ( Huang, Z; Jiang, W; Jin, X; Wang, M; Wang, Z; Xia, Q; Zhang, Y; Zheng, Y, 2014) |
| "DU-145 prostate cancer cells were treated with insulin-like growth factor (IGF) to activate the Akt-mTOR cascade or with the HDAC-inhibitor valproic acid (VPA) to induce histone H3 and H4 acetylation (aH3, aH4)." | 1.40 | Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells. ( Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Makarević, J; Mani, J; Reiter, M; Tawanaie, N; Tsaur, I, 2014) |
| " Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat." | 1.39 | Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. ( Carducci, MA; Gonzalez, M; Hammers, H; Kachhap, SK; Kaelber, NS; Kim, E; Kortenhorst, MS; Mendonca, J; van Diest, PJ; Wissing, MD, 2013) |
| "In this study, primary murine prostate cancer (PCa) cells were derived using the well-established TRAMP model." | 1.39 | Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. ( Bremmer, F; Burfeind, P; Kaulfuss, S; Neesen, J; Opitz, L; Salinas-Riester, G; Schweyer, S; Thelen, P; von Hardenberg, S; Witt, D, 2013) |
| "PC-3, DU-145, or LNCaP prostate cancer cells were treated with VPA (1 mM), IFNa (200 U/ml), or with the VPA-IFNa combination." | 1.38 | Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. ( Bartsch, G; Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarević, J; Tezeeh, P; Tsaur, I; Wedel, S; Wiesner, C, 2012) |
| "Valproic Acid (VPA) is a histone deacetylase inhibitor that holds promise for cancer therapy." | 1.37 | Does valproic acid induce neuroendocrine differentiation in prostate cancer? ( Carducci, M; Chowdhury, WH; Lupold, SE; Netto, G; Rodriguez, R; Shabbeer, S; Sidana, A; Toubaji, A; Wang, M, 2011) |
| "In this study, we show in prostate cancer cells that valproic acid (VPA) at low concentrations has minimal cytotoxic effects yet can significantly increase radiation-induced apoptosis." | 1.37 | Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. ( Chen, X; Radany, EH; Wong, JY; Wong, P, 2011) |
| " Since strong anti-tumor properties became evident with respect to cell growth and adhesion dynamics, the triple drug combination might provide progress in the treatment of advanced prostate cancer." | 1.37 | Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. ( Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarević, J; Seibel, JM; Tsaur, I; Waaga-Gasser, A; Wedel, S, 2011) |
| "In vitro and in vivo VPA treatment of prostate cancer cell lines results in significant dose- and time-dependent changes in nuclear structure." | 1.35 | Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. ( Carducci, MA; Chowdhury, WH; Isharwal, S; Kortenhorst, MS; Marlow, C; Rodriguez, R; van Diest, PJ; Veltri, RW, 2009) |
| "Treatment with valproic acid was able to increase the percentage of PTEN-positive cultures up to 80 and 74% for PTEN protein and mRNA determination, respectively." | 1.35 | Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. ( Biordi, L; Festuccia, C; Ficorella, C; Flati, V; Gravina, GL; Martella, F; Ricevuto, E; Tombolini, V, 2009) |
| "Valproic acid (VPA) is a promising anticancer agent recently assigned to the class of histone deacetylase (HDAC) inhibitors." | 1.35 | Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. ( Angelucci, A; Bologna, M; Cerù, MP; Cimini, A; Cristiano, L; Dolo, V; Miano, R; Millimaggi, D; Muzi, P; Vicentini, C, 2008) |
| "Valproic acid (VPA), is a drug approved by the FDA for epilepsy and bipolar disorders." | 1.34 | Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. ( Carducci, MA; Galloway, N; Kachhap, S; Kortenhorst, MS; Rodriguez, R; Shabbeer, S, 2007) |
| "LNCaP prostate cancer cells were treated with 5 mmol/L VPA or 100 micromol/L tectorigenin and transfected with small interfering RNA (siRNA) against ERbeta." | 1.34 | The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. ( Burfeind, P; Kaulfuss, S; Ringert, RH; Schweyer, S; Stettner, M; Strauss, A; Thelen, P, 2007) |
| "Valproic acid (VPA) is an established drug in the long-term therapy of seizure disorders." | 1.33 | Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. ( Carducci, M; Chen, CL; Chowdhury, W; Höti, N; Rodriguez, R; Shabbeer, S; Sung, J; Xia, Q, 2006) |
| "Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARgamma agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy." | 1.33 | Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. ( Abella, A; Annicotte, JS; Berthe, ML; Culine, S; Dubus, P; Fajas, L; Fritz, V; Iankova, I; Iborra, F; Maudelonde, T; Miard, S; Noël, D; Pillon, A; Sarruf, D, 2006) |
| "Valproic acid is a well-known antiepileptic drug that was recently discovered to have a wide-spectrum antitumoral action in several tumors." | 1.33 | Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. ( Angelucci, A; Bernardini, S; Bologna, M; Dolo, V; Federici, G; Gravina, GL; Miano, R; Millimaggi, D; Valentini, A; Vicentini, C, 2006) |
| "Valproic acid treatment caused a marked inhibition of histone deacetylases activity." | 1.32 | Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. ( Hemmerlein, B; Ringert, RH; Schweyer, S; Seseke, F; Thelen, P; Wuttke, W, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (32.61) | 29.6817 |
| 2010's | 29 (63.04) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, ZH | 1 |
| Kopeček, J | 1 |
| Iannelli, F | 1 |
| Roca, MS | 1 |
| Lombardi, R | 1 |
| Ciardiello, C | 1 |
| Grumetti, L | 1 |
| De Rienzo, S | 1 |
| Moccia, T | 1 |
| Vitagliano, C | 1 |
| Sorice, A | 1 |
| Costantini, S | 1 |
| Milone, MR | 1 |
| Pucci, B | 1 |
| Leone, A | 1 |
| Di Gennaro, E | 1 |
| Mancini, R | 1 |
| Ciliberto, G | 1 |
| Bruzzese, F | 1 |
| Budillon, A | 1 |
| Pang, B | 1 |
| Zhang, J | 1 |
| Zhang, X | 1 |
| Yuan, J | 1 |
| Shi, Y | 1 |
| Qiao, L | 1 |
| Tran, LNK | 1 |
| Kichenadasse, G | 1 |
| Sykes, PJ | 1 |
| Bhat, J | 1 |
| Dubin, S | 1 |
| Dananberg, A | 1 |
| Quabius, ES | 1 |
| Fritsch, J | 1 |
| Dowds, CM | 1 |
| Saxena, A | 1 |
| Chitadze, G | 1 |
| Lettau, M | 1 |
| Kabelitz, D | 1 |
| Qi, G | 1 |
| Lu, G | 2 |
| Yu, J | 1 |
| Zhao, Y | 1 |
| Wang, C | 1 |
| Zhang, H | 2 |
| Xia, Q | 5 |
| Chachadi, VB | 1 |
| Ali, MF | 1 |
| Cheng, PW | 1 |
| Kortenhorst, MS | 5 |
| Wissing, MD | 2 |
| Rodríguez, R | 7 |
| Kachhap, SK | 2 |
| Jans, JJ | 1 |
| Van der Groep, P | 1 |
| Verheul, HM | 2 |
| Gupta, A | 1 |
| Aiyetan, PO | 1 |
| van der Wall, E | 1 |
| Carducci, MA | 5 |
| Van Diest, PJ | 3 |
| Marchionni, L | 1 |
| Mendonca, J | 1 |
| Kaelber, NS | 1 |
| Gonzalez, M | 1 |
| Kim, E | 1 |
| Hammers, H | 1 |
| Jiang, W | 2 |
| Zheng, Y | 1 |
| Huang, Z | 1 |
| Wang, M | 4 |
| Zhang, Y | 2 |
| Wang, Z | 1 |
| Jin, X | 2 |
| Makarević, J | 4 |
| Tawanaie, N | 1 |
| Juengel, E | 7 |
| Reiter, M | 1 |
| Mani, J | 1 |
| Tsaur, I | 5 |
| Bartsch, G | 2 |
| Haferkamp, A | 6 |
| Blaheta, RA | 7 |
| Lan, X | 1 |
| Yuan, C | 1 |
| Mao, S | 1 |
| Chen, Y | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Terao, T | 1 |
| Katayama, Y | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 1 |
| Wang, L | 2 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, X | 1 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Liu, X | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Liu, L | 1 |
| Wang, X | 2 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Chen, Z | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Chelluri, R | 1 |
| Caza, T | 1 |
| Woodford, MR | 1 |
| Reeder, JE | 1 |
| Bratslavsky, G | 1 |
| Byler, T | 1 |
| Zahurak, M | 1 |
| Shabbeer, S | 5 |
| Kachhap, S | 2 |
| Galloway, N | 2 |
| Parmigiani, G | 1 |
| Isharwal, S | 1 |
| Chowdhury, WH | 4 |
| Marlow, C | 1 |
| Veltri, RW | 1 |
| Gravina, GL | 2 |
| Biordi, L | 1 |
| Martella, F | 1 |
| Flati, V | 1 |
| Ricevuto, E | 1 |
| Ficorella, C | 1 |
| Tombolini, V | 1 |
| Festuccia, C | 1 |
| Gavrilov, V | 1 |
| Leibovich, Y | 1 |
| Ariad, S | 1 |
| Lavrenkov, K | 1 |
| Shany, S | 1 |
| Wedel, S | 5 |
| Hudak, L | 6 |
| Seibel, JM | 4 |
| Oppermann, E | 1 |
| Sidana, A | 2 |
| Toubaji, A | 1 |
| Netto, G | 2 |
| Carducci, M | 3 |
| Lupold, SE | 3 |
| Wiesner, C | 3 |
| Chen, X | 1 |
| Wong, JY | 1 |
| Wong, P | 1 |
| Radany, EH | 1 |
| Fortson, WS | 1 |
| Kayarthodi, S | 1 |
| Fujimura, Y | 1 |
| Xu, H | 1 |
| Matthews, R | 1 |
| Grizzle, WE | 1 |
| Rao, VN | 1 |
| Bhat, GK | 1 |
| Reddy, ES | 1 |
| Ouyang, DY | 2 |
| Ji, YH | 1 |
| Saltis, M | 1 |
| Xu, LH | 2 |
| Zhang, YT | 2 |
| Zha, QB | 1 |
| Cai, JY | 2 |
| He, XH | 2 |
| Chou, YW | 1 |
| Chaturvedi, NK | 1 |
| Ouyang, S | 1 |
| Lin, FF | 1 |
| Kaushik, D | 1 |
| Wang, J | 1 |
| Kim, I | 1 |
| Lin, MF | 1 |
| Waaga-Gasser, A | 1 |
| Zhang, L | 1 |
| Wang, G | 1 |
| Song, C | 1 |
| Kang, J | 1 |
| Stettner, M | 2 |
| Krämer, G | 1 |
| Strauss, A | 3 |
| Kvitkina, T | 1 |
| Ohle, S | 1 |
| Kieseier, BC | 1 |
| Thelen, P | 5 |
| Tezeeh, P | 1 |
| Zeng, LH | 1 |
| Ren, S | 1 |
| Krahn, L | 1 |
| Bremmer, F | 2 |
| Brehm, R | 1 |
| Loertzer, H | 1 |
| Witt, D | 1 |
| Burfeind, P | 2 |
| von Hardenberg, S | 1 |
| Opitz, L | 1 |
| Salinas-Riester, G | 1 |
| Schweyer, S | 3 |
| Neesen, J | 1 |
| Kaulfuss, S | 2 |
| Hemmerlein, B | 1 |
| Wuttke, W | 1 |
| Seseke, F | 1 |
| Ringert, RH | 2 |
| Sung, J | 2 |
| Chowdhury, W | 1 |
| Chen, CL | 2 |
| Höti, N | 1 |
| Cohen, M | 1 |
| Sachs, MD | 1 |
| Li, Y | 1 |
| Lakshmanan, Y | 1 |
| Yung, BY | 1 |
| Annicotte, JS | 1 |
| Iankova, I | 1 |
| Miard, S | 1 |
| Fritz, V | 1 |
| Sarruf, D | 1 |
| Abella, A | 1 |
| Berthe, ML | 1 |
| Noël, D | 1 |
| Pillon, A | 1 |
| Iborra, F | 1 |
| Dubus, P | 1 |
| Maudelonde, T | 1 |
| Culine, S | 1 |
| Fajas, L | 1 |
| Angelucci, A | 2 |
| Valentini, A | 2 |
| Millimaggi, D | 2 |
| Miano, R | 3 |
| Dolo, V | 2 |
| Vicentini, C | 2 |
| Bologna, M | 2 |
| Federici, G | 2 |
| Bernardini, S | 2 |
| Biancolella, M | 1 |
| Amati, F | 1 |
| Gravina, P | 1 |
| Chillemi, G | 1 |
| Farcomeni, A | 1 |
| Bueno, S | 1 |
| Vespasiani, G | 1 |
| Desideri, A | 1 |
| Novelli, G | 1 |
| Gao, D | 1 |
| Lv, J | 1 |
| Wedel, SA | 1 |
| Sparatore, A | 1 |
| Soldato, PD | 1 |
| Al-Batran, SE | 1 |
| Atmaca, A | 1 |
| Jonas, D | 1 |
| Muzi, P | 1 |
| Cristiano, L | 1 |
| Cimini, A | 1 |
| Cerù, MP | 1 |
| Iacopino, F | 1 |
| Urbano, R | 1 |
| Graziani, G | 1 |
| Muzi, A | 1 |
| Navarra, P | 1 |
| Sica, G | 1 |
2 reviews available for valproic acid and Cancer of Prostate
| Article | Year |
|---|---|
Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.
Topics: Animals; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; | 2019 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
44 other studies available for valproic acid and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug | 2014 |
Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle Pr | 2020 |
Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C/EBPα/SREBP-1 pathway.
Topics: Apoptosis; CCAAT-Enhancer-Binding Proteins; Humans; Lipogenesis; Male; Neoplasm Proteins; PC-3 Cells | 2021 |
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Topics: Acetylation; Cell Line, Tumor; GPI-Linked Proteins; Histocompatibility Antigens Class I; Histone Dea | 2019 |
Up-regulation of TIF1γ by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-β/Smad signaling pathway.
Topics: Animals; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Ge | 2019 |
Prostatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis a.
Topics: CA-19-9 Antigen; Cell Line; Glycoproteins; Glycosyltransferases; Histone Deacetylase Inhibitors; His | 2013 |
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Topics: Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; | 2013 |
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Therapy, Combination; Histone Dea | 2013 |
Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.
Topics: Cell Line, Tumor; Cell Movement; Down-Regulation; Enzyme Inhibitors; Humans; Male; Neoplasm Invasive | 2014 |
Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
Topics: Acetylation; Blotting, Western; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetyl | 2014 |
Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
Topics: Animals; Anticonvulsants; Apoptosis; Blotting, Western; Cell Proliferation; Epithelial-Mesenchymal T | 2016 |
Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Neovascu | 2016 |
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expressi | 2008 |
Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Nucleus; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Inh | 2009 |
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer.
Topics: Androgen Antagonists; Apoptosis; Azacitidine; Blotting, Western; Cells, Cultured; Epigenesis, Geneti | 2009 |
A combined pretreatment of 1,25-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells.
Topics: Apoptosis; Calcitriol; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Screening | 2010 |
Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Topics: Adenocarcinoma; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, A | 2011 |
Does valproic acid induce neuroendocrine differentiation in prostate cancer?
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Chromogranin A; Humans; Male; Mice; Mice, Nude; Neu | 2011 |
Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Move | 2011 |
Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis.
Topics: Acetylation; Apoptosis; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Lysine; Male; Memb | 2011 |
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Topics: Cell Adhesion; Cell Movement; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Histone Deac | 2011 |
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Topics: Acetylation; Animals; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Chlorocebus | 2011 |
Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: an iTRTAQ-based quantitative proteomic analysis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Damage; Drug Synergism; Energy Metabolism; G | 2011 |
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Topics: Acid Phosphatase; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Ce | 2011 |
Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Cycle; Cell Growth Processes; Ce | 2011 |
Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression.
Topics: Animals; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Histone | 2011 |
Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer.
Topics: Aged; Anticonvulsants; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Prognosis; | 2012 |
Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Topics: Animals; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Histone Dea | 2012 |
Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5.
Topics: Adaptor Proteins, Signal Transducing; Alternative Splicing; Autophagy; Autophagy-Related Protein 12; | 2013 |
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Topics: Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitor | 2012 |
Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Histone Deacet | 2013 |
Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cy | 2013 |
Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Topics: Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; E | 2004 |
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Topics: Acetylation; Animals; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Drug Administration Sc | 2006 |
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Topics: Acetylation; Animals; Cell Line, Tumor; Cell Movement; Cell Survival; Coxsackie and Adenovirus Recep | 2006 |
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Topics: Animals; Cadherins; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progressio | 2006 |
Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Fas Ligand Protei | 2006 |
Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Topics: Cell Differentiation; Cell Line, Tumor; Down-Regulation; Gene Expression Profiling; Gene Expression | 2007 |
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senesc | 2007 |
Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Topics: Acetylation; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhib | 2007 |
The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment.
Topics: Blotting, Western; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Estrogen Receptor beta; His | 2007 |
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
Topics: Animals; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Histone Deacetylase | 2008 |
Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Topics: Adenocarcinoma; Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transdifferentiation; | 2008 |
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells.
Topics: Blotting, Western; Cadherins; Cell Proliferation; Dihydrotestosterone; Drug Resistance, Neoplasm; En | 2008 |